Grant: Alliance Grants
University of Toronto
$50,000.00
Rapid development of automated antiviral lighting systems for use as a COVID-19 prevention tool_x000d_
EF 2020-21
Résumé
Safe Antivirus Technologies Inc. (SATI) is developing novel antiviral lighting systems (AVLS) that utilize ultraviolet light (UV) as a powerful antiviral tool to automatically sanitize large public spaces. The AVLS will enable commercial and institutional buildings to significantly reduce the transmission of viruses from commonly touched surfaces, offering enhanced protection during the COVID-19 pandemic and future outbreaks. The AVLS will also supply the standard "white-light" room lighting, enabling this unique lighting system to be readily installed in place of fluorescent tubes and LEDs in existing light fixtures. Exposure to UV wavelengths is a well-described sanitization strategy for viruses in the scientific literature and can achieve rapid inactivation of a broad range of viruses via a mechanism of non-specific DNA/RNA damage. SATI is applying sanitizing UV light to the COVID-19 pandemic by developing the AVLS as a rapidly deployed, infection control intervention against SARS-CoV-2. This project will provide all of the antiviral efficacy testing for the development and commercialization of the AVLS, performed under the supervision of Dr. Christina Guzzo, an Assistant Professor of Virology at the University of Toronto Scarborough. Dr. Guzzo's team will perform tests to delineate the appropriate UV illumination parameters for optimal antiviral activity, and subsequent field testing to ensure durable antiviral activity in representative commercial sites where the AVLS can be deployed. The AVLS includes patent-pending technologies and will be the first lighting system on the market to include real-time feedback controls, with UV light that is fully integrated with required room illumination, enabling ease of installation in offices, boardrooms, public washrooms, airplanes, subways, buses and other high-traffic areas to minimize the spread of viruses in everyday interactions. This project is critically needed to validate antiviral efficacy and guide commercial design of the AVLS. Upon completion of this project the AVLS can be rapidly deployed to improve occupational health and safety, bringing Canadians back to a safer workplace, and decreasing the likelihood of viral transmission in daily encounters.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
552685-2020
Name nom
Guzzo, Christina
Department département
Scarborough College
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Rapid development of automated antiviral lighting systems for use as a COVID-19 prevention tool_x000d_
Keyword
NSERC
Application summary
Safe Antivirus Technologies Inc. (SATI) is developing novel antiviral lighting systems (AVLS) that utilize ultraviolet light (UV) as a powerful antiviral tool to automatically sanitize large public spaces. The AVLS will enable commercial and institutional buildings to significantly reduce the transmission of viruses from commonly touched surfaces, offering enhanced protection during the COVID-19 pandemic and future outbreaks. The AVLS will also supply the standard "white-light" room lighting, enabling this unique lighting system to be readily installed in place of fluorescent tubes and LEDs in existing light fixtures. Exposure to UV wavelengths is a well-described sanitization strategy for viruses in the scientific literature and can achieve rapid inactivation of a broad range of viruses via a mechanism of non-specific DNA/RNA damage. SATI is applying sanitizing UV light to the COVID-19 pandemic by developing the AVLS as a rapidly deployed, infection control intervention against SARS-CoV-2. This project will provide all of the antiviral efficacy testing for the development and commercialization of the AVLS, performed under the supervision of Dr. Christina Guzzo, an Assistant Professor of Virology at the University of Toronto Scarborough. Dr. Guzzo's team will perform tests to delineate the appropriate UV illumination parameters for optimal antiviral activity, and subsequent field testing to ensure durable antiviral activity in representative commercial sites where the AVLS can be deployed. The AVLS includes patent-pending technologies and will be the first lighting system on the market to include real-time feedback controls, with UV light that is fully integrated with required room illumination, enabling ease of installation in offices, boardrooms, public washrooms, airplanes, subways, buses and other high-traffic areas to minimize the spread of viruses in everyday interactions. This project is critically needed to validate antiviral efficacy and guide commercial design of the AVLS. Upon completion of this project the AVLS can be rapidly deployed to improve occupational health and safety, bringing Canadians back to a safer workplace, and decreasing the likelihood of viral transmission in daily encounters.